Suven Life Sciences Gets Product Patents in China, Sri Lanka | CORPORATE ETHOS

Suven Life Sciences Gets Product Patents in China, Sri Lanka

By: | January 18, 2018

Jan 18: Hyderabad-based biopharma major Suven Life Sciences Ltd on Thursday announced the company has been granted one  product patent from China (CN105164119) and another one product patent from Sri Lanka (18067) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2033 and 2032 respectively.

According to the company, the granted claims of the patents include the class of selective 5-HT4 and H3 compounds respectively and are being developed as therapeutic agents for major depressive disorders and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Narcolepsy, Parkinson and Schizophrenia respectively.

Commenting on the development, Venkat Jasti, CEO of Suven, said, “we are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally.”

Suven Life shares were trading at Rs 207, up 1.40% from the previous closing of Rs 204.15, on BSE at 1.23 pm today.